# Silibin B

**Canonical URL:** https://ingredients.hermeticasuperfoods.com/ingredients/silibin-b
**Data Source:** Hermetica Superfoods Ingredient Encyclopedia
**Updated:** 2026-03-30
**Evidence Score:** 2 / 10
**Category:** Compound
**Also Known As:** Silybin B, Silybum marianum flavonolignan B, Milk thistle diastereomer B, Silymarin component B, 2,3-Dehydrosilybin B diastereomer

## Overview

Silibin B is one of two diastereomers of silybin, a flavonolignan extracted from milk thistle (Silybum marianum), and exerts its primary effects through [antioxidant activity](/ingredients/condition/antioxidant) and inhibition of hepatic lipid peroxidation. It modulates NF-κB signaling and CYP enzyme activity to deliver [hepatoprotective](/ingredients/condition/detox), [anti-inflammatory](/ingredients/condition/inflammation), and anticancer actions at the cellular level.

## Health Benefits

• [Hepatoprotective](/ingredients/condition/detox) properties, as demonstrated in vitro and in vivo studies.[3] • [Antioxidant activity](/ingredients/condition/antioxidant) noted in pharmacological research.[3] • [Anti-inflammatory](/ingredients/condition/inflammation) effects observed in broader silybin studies.[3] • Potential anticancer properties based on preclinical data.[3] • [Neuroprotective effect](/ingredients/condition/cognitive)s indicated in animal studies.[3]

## Mechanism of Action

Silibin B scavenges [reactive oxygen species](/ingredients/condition/antioxidant) (ROS) and inhibits lipid peroxidation by donating hydrogen atoms from its phenolic hydroxyl groups, protecting hepatocyte membranes from oxidative damage. It suppresses NF-κB and STAT3 transcription factor activation, thereby downregulating [pro-inflammatory cytokine](/ingredients/condition/inflammation)s such as TNF-α and IL-6. Additionally, silibin B inhibits cytochrome P450 enzymes (notably CYP3A4 and CYP2C9) and modulates P-glycoprotein activity, influencing drug [metabolism](/ingredients/condition/weight-management) and cellular detoxification pathways.

## Clinical Summary

Most evidence for silibin B derives from preclinical in vitro and animal studies, where it has demonstrated dose-dependent hepatocellular protection against carbon tetrachloride and acetaminophen-induced liver injury. Human clinical trials typically use standardized silymarin or silybin-phosphatidylcholine complexes (e.g., Legalon SIL 140 mg IV) rather than isolated silibin B, limiting diastereomer-specific conclusions. A pharmacokinetic study in healthy volunteers showed that silibin B exhibits higher oral bioavailability than silibin A when formulated as a phospholipid complex, reaching measurable plasma concentrations with 360 mg silybin complex doses. Overall, the clinical evidence base is preliminary, and large randomized controlled trials isolating silibin B's effects remain lacking.

## Nutritional Profile

Silibin B (also spelled Silybin B) is a flavonolignan and one of the two major diastereomers of silybin, the primary bioactive component of silymarin extracted from milk thistle (Silybum marianum). It is not a conventional food nutrient but a pharmacologically active phytochemical compound. As a pure isolated compound, it does not provide meaningful macronutrients (proteins, carbohydrates, fats) or conventional micronutrients (vitamins, minerals) in supplemental doses. Bioactive compound concentration: Silibin B typically constitutes approximately 20–30% of the silybin fraction within silymarin extract, with silymarin itself comprising roughly 1.5–3% of milk thistle seed dry weight. In standardized silymarin supplements (standardized to 70–80% silymarin), silybin (combined A+B diastereomers) may represent 30–65% of total silymarin content. Bioavailability notes: Silibin B exhibits notably poor oral bioavailability (~0.5–1% in free form) due to its hydrophilic nature, low [intestinal permeability](/ingredients/condition/gut-health), and significant first-pass [metabolism](/ingredients/condition/weight-management). It undergoes extensive Phase II conjugation (glucuronidation and sulfation) in intestinal and hepatic tissue. Phospholipid complexes (e.g., silybin-phosphatidylcholine phytosome formulations) have been shown to increase bioavailability by 4–10 fold compared to free silybin. Plasma half-life is approximately 6–8 hours. Silibin B has demonstrated slightly different pharmacokinetic behavior compared to its diastereomer Silibin A, with some studies suggesting differential hepatic uptake and metabolic processing between the two forms.

## Dosage & Preparation

No clinically studied dosage ranges for silibin B specifically are available. Silibinin (A/B mixture) dosing is not standardized. Consult a healthcare provider before starting any new supplement.

## Safety & Drug Interactions

Silibin B is generally well tolerated at standard silymarin-equivalent doses (140–420 mg/day), with mild gastrointestinal disturbances such as nausea, bloating, and loose stools being the most commonly reported adverse effects. Due to inhibition of CYP3A4, CYP2C9, and UGT enzymes, silibin B may elevate plasma concentrations of co-administered drugs including statins, anticoagulants like warfarin, and certain chemotherapeutics, necessitating clinical monitoring. It may exhibit additive hypoglycemic effects when combined with insulin or oral antidiabetic agents, and caution is warranted in patients on immunosuppressants such as tacrolimus. Safety data in pregnancy and lactation are insufficient, and use is generally not recommended in these populations without medical supervision.

## Scientific Research

There is no specific clinical trial data or meta-analyses available for silibin B alone. Existing research focuses on the effects of the silymarin complex or the silybin A/B mixture, with no specific PMIDs provided.

## Historical & Cultural Context

There is no historical or traditional use information available for silibin B specifically in the research dossier.

## Synergistic Combinations

Curcumin, Resveratrol, Quercetin, Vitamin E, Green tea extract

## Frequently Asked Questions

### What is the difference between silibin A and silibin B?

Silibin A and silibin B are diastereomers sharing the same molecular formula (C25H22O10) but differing in the stereochemical configuration at C-7 and C-8 of the 1,4-dioxane ring connecting the taxifolin and coniferyl alcohol moieties. Pharmacokinetic studies indicate silibin B achieves approximately 1.5–2 times higher plasma area under the curve (AUC) than silibin A following oral administration of phospholipid complexes, suggesting superior bioavailability. This stereochemical difference also appears to influence relative potency in certain antioxidant and CYP inhibition assays.

### Can silibin B help protect the liver from alcohol damage?

Preclinical studies show silibin B reduces ethanol-induced hepatocyte apoptosis by suppressing oxidative stress markers, including malondialdehyde (MDA) levels, and upregulating antioxidant enzymes such as superoxide dismutase (SOD) and glutathione peroxidase (GPx). In rodent models of alcoholic liver disease, silybin treatment reduced serum ALT and AST enzyme elevations by 40–60% compared to untreated controls. However, no large-scale randomized controlled trials have specifically evaluated isolated silibin B in human alcoholic liver disease, so clinical recommendations remain extrapolated from broader silymarin research.

### What is the recommended dosage of silibin B as a supplement?

There is no established dosage specific to isolated silibin B; most clinical protocols use standardized silymarin extracts containing 70–80% silybin (A+B combined) at doses of 140–420 mg of silymarin three times daily, equating to roughly 100–300 mg total silybin per dose. For enhanced bioavailability, silybin-phosphatidylcholine complexes (Siliphos) at 360–720 mg/day have been used in hepatology studies. Individuals should consult a healthcare provider for personalized dosing, particularly when managing liver disease or taking interacting medications.

### Does silibin B have anticancer properties?

Preclinical data indicate silibin B inhibits cancer cell proliferation by inducing G1-phase cell cycle arrest through downregulation of cyclin D1 and CDK4, and promotes apoptosis via the intrinsic mitochondrial pathway involving caspase-3 and caspase-9 activation. In vitro studies have demonstrated activity against prostate, breast, colon, and hepatocellular carcinoma cell lines at concentrations of 25–100 µM. These findings are promising but have not yet been confirmed in large human clinical trials, so silibin B should not be considered a standalone cancer treatment.

### Does silibin B interact with any medications?

Silibin B inhibits cytochrome P450 enzymes CYP3A4, CYP2C9, and CYP2D6, as well as UDP-glucuronosyltransferases (UGTs), which can slow the metabolism of drugs including warfarin, statins (e.g., atorvastatin), HIV antiretrovirals (e.g., indinavir), and certain chemotherapy agents, potentially raising their plasma levels and toxicity risk. It also inhibits P-glycoprotein efflux, which may further alter drug bioavailability. Patients on narrow therapeutic index drugs should inform their physician before using silibin B or silymarin-containing supplements, as dosage adjustments may be necessary.

### What is the bioavailability of silibin B and how can it be improved?

Silibin B has relatively poor bioavailability when taken orally due to its low water solubility and extensive first-pass metabolism in the liver. Formulations using phospholipid complexes (phytosome technology) or standardized silymarin extracts that contain silibin B have been shown to significantly enhance absorption and plasma concentrations. Taking silibin B with fatty meals may also improve its absorption, as it is a lipophilic compound.

### Is silibin B safe to take during pregnancy and breastfeeding?

There is limited clinical data on silibin B safety during pregnancy and breastfeeding, so supplementation is generally not recommended during these periods without medical supervision. While traditional silymarin (which contains silibin B) has been used historically, pregnant and nursing women should consult their healthcare provider before use, as adequate safety studies in these populations have not been conducted.

### What does current clinical research show about silibin B's neuroprotective effects?

Animal studies and in vitro research have demonstrated that silibin B possesses neuroprotective properties through antioxidant and anti-inflammatory mechanisms, including protection against oxidative stress-induced neuronal damage. However, human clinical trials specifically evaluating silibin B for neurological conditions remain limited, and more research is needed to establish efficacy in patients with neurodegenerative disorders or brain injury.

---

*Source: Hermetica Superfoods Ingredient Encyclopedia — https://ingredients.hermeticasuperfoods.com*
*License: CC BY-NC-SA 4.0 — Attribution required. Commercial use: admin@hermeticasuperfoods.com*